Comparing FDA Guidance With Reality & Why Real‑World Evidence Still Cannot Stand Alone

• Understanding why best practice RWE guidance does not guarantee acceptance in practice
• Identifying sources of subjectivity and uncertainty in HTA committee decision making
• Designing RWE strategies that improve predictability across markets and bodies

Speakers:

Eugean Jiwanmall

Lead Research Analyst for Medical Policy & Health Technology Evaluation

Independence Blue Cross Family of Companies & Independence Health Group